Disclosed are pharmaceutical formulations comprising monoclonal anti-factor D antibodies and their use for use in the treatment of complement-related eye diseases. Formulations include pre-lyophilized, lyophilized and reconstituted stable liquid formulations of anti-factor D antibodies including lamparizumab. [Selection] Figure 3モノクローナル抗D因子抗体を含む薬学的製剤、並びにその製造及び補体関連の眼疾患の治療のための使用が開示される。製剤は、ランパリズマブを含む抗D因子抗体の、プレ凍結乾燥、凍結乾燥、及び再構成された安定な液体製剤を含む。【選択図】図3